Compare OXSQ & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | TNYA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 157.9M |
| IPO Year | N/A | 2021 |
| Metric | OXSQ | TNYA |
|---|---|---|
| Price | $1.94 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 02-27-2026 | 03-09-2026 |
| Dividend Yield | ★ 21.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $0.36 |
| 52 Week High | $2.87 | $2.35 |
| Indicator | OXSQ | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 62.11 | 50.19 |
| Support Level | $1.84 | $0.65 |
| Resistance Level | $1.98 | $0.79 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 83.72 | 89.84 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.